source
- San Diego biotech BlossomHill files for IPO to fund EGFR lung-cancer drug programBlossomHill Therapeutics, a San Diego oncology biotech focused on small‑molecule drugs, has filed an S‑1 registration statement to become a public company. The company, founded in February 2024 by…
- Insmed's inhaled PAH therapy shows durable efficacy in 12-month extension, bolstering $6B sales outlookInsmed reported that its inhalable prostanoid candidate, treprostinil palmitil inhalation powder (TPIP), maintained functional and biomarker benefits through a 12‑month open‑label extension in pati…